Lesson plan

PPTQ

PPTQ, is an analogue of the sedative and hypnotic drug methaqualone first identified as a sedative drug in 2018. It is a derivative of methaqualone with the 2-methyl group replaced by a phenyl ring and the o-tolyl group replaced by p-tolyl. It acts as a potent GABA A receptor positive allosteric modulator, acting primarily at the α 4 β 2 δ subtype and to a lesser extent at the α 1 β 2 γ 2S subtype, showing an overlap in its binding sites and modulatory activity with barbiturates and other sedatives such as propofol and etomidate, but acting in a way distinct from that of benzodiazepines. It has been sold as a designer drug and is reportedly up to 100x more potent than methaqualone as a sedative, and can similarly sometimes produce a paradoxical lowering of the seizure threshold. This makes methaqualone and its derivatives especially dangerous in overdose, as severely affected individuals can be simultaneously sedated to the point of unconsciousness but also experiencing convulsions, with administration of anticonvulsant drugs complicated by the need to avoid worsening sedation.

Back to article

Article summary

PPTQ, is an analogue of the sedative and hypnotic drug methaqualone first identified as a sedative drug in 2018. It is a derivative of methaqualone with the 2-methyl group replaced by a phenyl ring and the o-tolyl group replaced by p-tolyl. It acts as a potent GABA A receptor positive allosteric modulator, acting primarily at the α 4 β 2 δ subtype and to a lesser extent at the α 1 β 2 γ 2S subtype, showing an overlap in its binding sites and modulatory activity with barbiturates and other sedatives such as propofol and etomidate, but acting in a way distinct from that of benzodiazepines. It has been sold as a designer drug and is reportedly up to 100x more potent than methaqualone as a sedative, and can similarly sometimes produce a paradoxical lowering of the seizure threshold. This makes methaqualone and its derivatives especially dangerous in overdose, as severely affected individuals can be simultaneously sedated to the point of unconsciousness but also experiencing convulsions, with administration of anticonvulsant drugs complicated by the need to avoid worsening sedation.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.